GlassScriptPhysician profile
Ellen N Spremulli
NPI 1619922648
$6,299.62
in general payments reported to CMS, 2019-2025
49 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,410 · 2020: $2,732 · 2021: $358 · 2022: $1,306 · 2023: $479 · 2024: $15.12.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $494.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $493.78 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $2,504.14 | 2019-2022 | |
| E.R. Squibb & Sons, L.L.C. | $314.48 | 2019-2023 | |
| Novartis Pharmaceuticals Corporation | $267.30 | 2019-2023 | |
| Merck Sharp & Dohme LLC | $256.13 | 2019-2023 | Keytruda |
| Celgene Corporation | $242.21 | 2019-2023 | Pomalyst, Reblozyl |
| Covis Pharma Gmbh | $200.00 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $184.52 | 2019-2023 | Lynparza, Enhertu, Calquence |
| Seagen INC. | $182.40 | 2019-2023 | Adcetris |
| Incyte Corporation | $176.56 | 2019-2023 | Jakafi |
| Eisai INC. | $176.50 | 2019-2023 | |
| Takeda Pharmaceuticals U.S.A., INC. | $170.54 | 2019-2023 | Iclusig, Ninlaro |
| Janssen Biotech, INC. | $159.08 | 2019 | |
| Pharmacyclics LLC, An Abbvie Company | $152.53 | 2019-2023 | Imbruvica |
| Amgen INC. | $144.95 | 2019-2022 | |
| Exelixis INC. | $125.85 | 2019-2022 |
Show all 49 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ellen Spremulli listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.